|
|
|
|
| LEADER |
01627nam a22003015i 4500 |
| 001 |
978-1-59259-962-2 |
| 005 |
20190702061043.0 |
| 007 |
cr nn 008mamaa |
| 008 |
100301s2006 xxu| s |||| 0|eng d |
| 020 |
|
|
|a 9781592599622
|
| 024 |
7 |
|
|a 10.1385/1592599621
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Protein Tyrosine Kinases
|b From Inhibitors to Useful Drugs /
|c edited by Doriano Fabbro, Frank McCormick.
|
| 250 |
|
|
|a 1st ed. 2006.
|
| 260 |
# |
# |
|a Totowa, NJ :
|b Humana Press :
|b Imprint: Humana,
|c 2006.
|
| 300 |
|
|
|a XIII, 290 p.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Cancer Drug Discovery and Development,
|
| 505 |
0 |
|
|a Protein Tyrosine Kinases as Targets for Cancer and Other Indications -- Inhibitors of Signaling Interfaces -- PI3-Kinase Inhibition -- Src as a Target for Pharmaceutical Intervention -- Activated FLT3 Receptor Tyrosine Kinase as a Therapeutic Target In Leukemia -- JAK Kinases in Leukemias, Lymphomas, and Multiple Myeloma -- Glivec® (Gleevec®, Imatinib, STI571) -- Platelet-Derived Growth Factor -- Structural Biology of Protein Tyrosine Kinases -- Testing of Signal Transduction Inhibitors in Animal Models of Cancer -- Phosphoproteomics in Drug Discovery and Development.
|
| 650 |
|
0 |
|a Biochemistry.
|
| 650 |
1 |
4 |
|a Biochemistry, general.
|
| 700 |
1 |
|
|a Fabbro, Doriano.
|e editor.
|
| 700 |
1 |
|
|a McCormick, Frank.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 856 |
4 |
0 |
|u https://doi.org/10.1385/1592599621
|